Literature DB >> 26337624

Clinical response associated with radiographic regression of a cervicomedullary ependymoma in a NF2 patient treated by bevacizumab.

W I Essayed1,2, A Bernard3, M Kalamarides4,5.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26337624     DOI: 10.1007/s11060-015-1925-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  4 in total

1.  Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.

Authors:  Scott R Plotkin; Anat O Stemmer-Rachamimov; Fred G Barker; Chris Halpin; Timothy P Padera; Alex Tyrrell; A Gregory Sorensen; Rakesh K Jain; Emmanuelle di Tomaso
Journal:  N Engl J Med       Date:  2009-07-08       Impact factor: 91.245

2.  Bevacizumab for recurrent ependymoma.

Authors:  R M Green; T F Cloughesy; R Stupp; L M DeAngelis; E A Woyshner; D E Ney; A B Lassman
Journal:  Neurology       Date:  2009-11-17       Impact factor: 9.910

3.  Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.

Authors:  Fabio P Nunes; Vanessa L Merker; Dominique Jennings; Paul A Caruso; Emmanuelle di Tomaso; Alona Muzikansky; Fred G Barker; Anat Stemmer-Rachamimov; Scott R Plotkin
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

4.  C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma.

Authors:  Matthew Parker; Kumarasamypet M Mohankumar; Chandanamali Punchihewa; Ricardo Weinlich; James D Dalton; Yongjin Li; Ryan Lee; Ruth G Tatevossian; Timothy N Phoenix; Radhika Thiruvenkatam; Elsie White; Bo Tang; Wilda Orisme; Kirti Gupta; Michael Rusch; Xiang Chen; Yuxin Li; Panduka Nagahawhatte; Erin Hedlund; David Finkelstein; Gang Wu; Sheila Shurtleff; John Easton; Kristy Boggs; Donald Yergeau; Bhavin Vadodaria; Heather L Mulder; Jared Becksfort; Jared Becksford; Pankaj Gupta; Robert Huether; Jing Ma; Guangchun Song; Amar Gajjar; Thomas Merchant; Frederick Boop; Amy A Smith; Li Ding; Charles Lu; Kerri Ochoa; David Zhao; Robert S Fulton; Lucinda L Fulton; Elaine R Mardis; Richard K Wilson; James R Downing; Douglas R Green; Jinghui Zhang; David W Ellison; Richard J Gilbertson
Journal:  Nature       Date:  2014-02-19       Impact factor: 49.962

  4 in total
  4 in total

1.  Spinal ependymomas in NF2: a surgical disease?

Authors:  M Kalamarides; W Essayed; J P Lejeune; R Aboukais; O Sterkers; D Bernardeschi; M Peyre; S K Lloyd; S Freeman; C Hammerbeck-Ward; M Kellett; S A Rutherford; D G Evans; O Pathmanaban; A T King
Journal:  J Neurooncol       Date:  2017-11-29       Impact factor: 4.130

2.  Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort.

Authors:  Katrina A Morris; John F Golding; Claire Blesing; D Gareth Evans; Rosalie E Ferner; Karen Foweraker; Dorothy Halliday; Raj Jena; Catherine McBain; Martin G McCabe; Angela Swampillai; Nicola Warner; Shaun Wilson; Allyson Parry; Shazia K Afridi
Journal:  J Neurooncol       Date:  2016-10-28       Impact factor: 4.130

3.  Redefining germline predisposition in children with molecularly characterized ependymoma: a population-based 20-year cohort.

Authors:  Jon Foss-Skiftesvik; Ulrik Kristoffer Stoltze; Karin Wadt; René Mathiasen; Thomas van Overeem Hansen; Lise Barlebo Ahlborn; Erik Sørensen; Sisse Rye Ostrowski; Solvej Margrete Aldringer Kullegaard; Adrian Otamendi Laspiur; Linea Cecilie Melchior; David Scheie; Bjarne Winther Kristensen; Jane Skjøth-Rasmussen; Kjeld Schmiegelow
Journal:  Acta Neuropathol Commun       Date:  2022-08-25       Impact factor: 7.578

4.  Chemotherapy for adult patients with spinal cord gliomas.

Authors:  Dorothee Gramatzki; Jörg Felsberg; Bettina Hentschel; Oliver Bähr; Manfred Westphal; Gabriele Schackert; Jörg Christian Tonn; Ulrich Herrlinger; Markus Loeffler; Torsten Pietsch; Joachim Peter Steinbach; Guido Reifenberger; Patrick Roth; Michael Weller
Journal:  Neurooncol Pract       Date:  2021-03-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.